Treating anaemia: Deconstructing healthcare costs

Current Medical Research and Opinion, Supplement

Volumn 22, Issue 4, 2006, Pages

  Littlewood, Tim ^a   Zambrowski, Jean Jacques ^b   Cornes, Paul ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Anaemia; Cancer; Cost effectiveness; Economic models; Erythropoietin; Transfusion

Indexed keywords

CYANOCOBALAMIN; ERYTHROPOIETIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADJUVANT THERAPY; ANEMIA; BLOOD TRANSFUSION; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT;

EID: 33846024084     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X159597     Document Type: Review

References (52)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
2. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-6
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-21
4. Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anaemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56
5. Österborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;15(Suppl 1):S47-9
6. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9
7. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999;319:16-19
8. Jensen PD, Jensen FT, Christensen T, et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anaemias. Blood 2003;101:91-6
9. Barrett-Lee PJ, Bailey NP, O'Brien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-7
10. Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. Hematology Am Soc Hematol Educ Program 2001:422-32
11. Ludwig H, Rai K, Blade J, et al. Management of disease-related anaemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002;3:121-30
12. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
13. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anaemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-60
14. ten Bokkel Huinink WW, de Swart CAM, van Toorn DW, et al Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82
15. Österborg A, Brandberg Y, Molostova V, et al; Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94
16. Boogaerts M, Coiffier B, Kainz C; Epoetin β QOL Working Group. Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-95
17. Littlewood TJ, Bajetta E, Nortier JW, et al; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
18. Vansteenkiste J, Pirker R, Massuti B, et al; Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
19. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34
20. Demetri GD, Kris M, Wade J, et al; Procrit Study Group. Quality-of-life benefits in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25
21. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95
22. Casas F, Vinolas N, Ferrer F, et al. Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2003;55:116-24
23. de Castro J, Ordóñez A, Isla D, et al. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. Cancer Chemother Pharmacol 2006: Jul 28; [Epub ahead of print]
24. Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000;18:2755-61
25. Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991;31:318-23
26. Crémieux P-Y, Slavin MB, Fendrick M, Hiriak TC. The costs of cancer: cancer-related conditions can add dramatically to overall costs of care. J Manag Care Med 2002;6:12-19
27. Chaves PHM, Mody SH, Najib MM, et al. Anemia in the elderly is associated with increased healthcare costs and resource utilization. Blood 2003;102:2769 [abstract]
28. Penninx BW, Pahor M, Woodman RC, et al. Late-life anaemia identifies persons at risk for mortality and hospitalization. Blood 2003;102:881 [abstract]
29. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34 (Suppl 2):13-9
30. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640-50
31. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38
32. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-60
33. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003;95:190-7
34. Barnett A, Birnbaum H, Cremieux P-Y, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000;6:1243-51
35. Barnett A, Cremieux P-Y, Fendrick AM, et al. Anaemia-related costs for cancer patients. J Manag Care Med 2002;6:20-8
36. Nissenson AR, Wade S, Goodnough LT, et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005;11:565-74
37. Greenhalgh T. How to read a paper: papers that tell you what things cost (economic analyses). BMJ 1997;315:596-9
38. Barosi G, Marchetti M, Liberato NL. Cost effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:781-7
39. Martin SC, Gagnon DD, Zhang L, et al. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003;21:1153-69
40. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 1998;83:2588-96
41. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anaemia. Ann Pharmacother 1997;31:15-22
42. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995;35:427-30
43. Crémieux P-Y, Finkelstein SN, Berndt ER, et al. Cost-effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999;16:459-72
44. Szucs TD, Boogaerts M, Coiffier B, Kainz C. Cost-effectiveness of epoetin beta in the management of cancer-related anaemia. Hematol J 2001;(2 Suppl 1):67 [abstract 192]
45. Borget I, Tilleul P, Baud M, et al. Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anaemia: a Markov analysis. Lung Cancer 2006;51:369-76
46. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(Suppl 2):4-12
47. Bosanquet N, Tolley K. Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 2003;19:643-50
48. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-9
49. Itri LM. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002;29(Suppl 8):81-7
50. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7
51. Hedenus M, Birgegârd G, Näsman P, et al. Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non iron-depleted patients with lymphoproliferative disorders: results of the NIFe study. Haematologica/Hematol J 2006;91 (Suppl 1):0996 [abstract]
52. Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anaemia. Cancer 2006;107:1909-17